Skip to main content

Table 1 Study population characteristics

From: Impact of rifampicin dose in bone and joint prosthetic device infections due to Staphylococcus spp: a retrospective single-center study in France

  Total Low-dose (< 10 mg/kg/d) Intermediate-dose (10-20 mg/kg/d) High-dose (> 20 mg/kg/d)
Total, n (%) 411 27 (6.6) 319 (77.6) 65 (15.8)
Male sex, n (%) 223 (54.3) 9 (33.3) 181 (56.7) 33 (50.8)
Age, years (mean, [IQR]) 64.5 [55–76] 69.2 [61–80] 64.1 [55–76] 64.6 [51–78]
Weight, kg (mean, [IQR]) 82.5 [68–95] 99.8 [75–125] 84.5 [70–95] 65.6 [55–80]
BMI, kg/m2 (mean, [IQR]) 29.1 [23. 9–33] 35.8 [27.5–42] 29.4 [24.8–33.1] 24.2 [20.4–29]
Obesity, n (%) 167 (40.1) 20 (74.1) 133 (41.7) 14 (21.6)
Comorbidities, n (%)
 Chronic alcohol consumption 34 (8.3) 2 (7.4) 26 (8.2) 6 (9.2)
 Diabetes 74 (8) 7 (26) 63 (19.7) 4 (6.2)
 Chronic kidney disease
> grade IIIB
18 (4.4) 3 (11.1) 13 (4.1) 2 (3.1)
 Immune deficiency factor 33 (10.5) 1 (3.7) 26 (8.2) 6 (9.2)
 Chronic liver disease 6 (1.5) 1 (3.7) 4 (1.3) 1 (1.5)
Infection site, n (%)
 Hip 164 (39.9) 7 (26) 131 (41.1) 26 (40)
 Femur 17 (4.1) 0 (0) 10 (3.1) 7 (10.8)
 Knee 123 (9.9) 13 (48.1) 94 (29.5) 16 (24.6)
 Tibia 29 (7.1) 2 (7.4) 25 (7.8) 4 (6.2)
 Ankle 38 (9.2) 4 (14.8) 28 (8.8) 4 (6.2)
 Foot 13 (3.2) 0 (0) 11 (3.4) 2 (3.1)
 Upper limb ** 28 (6.6) 1 (3.7) 20 (6.3) 6 (9.2)
Delay of PJI
 Acute prosthesis infection (< 3 months) 196 (47.7) 13 (48.1) 147 (46.1) 36 (55.4)
 Chronic prosthesis infection (> 12 months) 130 (31.6) 9 (33.3) 104 (32.6) 17 (26.2)
Surgical method
 Prosthesis replacement 212 (51.6) 13 (48.1) 173 (54.2) 24 (36.9)
 Prosthetic device removal 78 (19.0) 2 (7.4) 59 (18.5) 15 (23.1)
 Implant retention 83 (20.7) 5 (18,5) 59 (18.5) 19 (29.2)
 Arthrodesis 5 (1.2) 1 (3.7) 4 (1.3) 0 (0)
 Explantation 31 (7.5) 1 (3.7) 23 (7.2) 6 (9.2)
 No surgery 2 0 1 1
Germs, n (%)
Staphylococcus aureus 289 (70.3) 19 (70.4) 229 (71.8) 42 (64.6)
  Methicillin-sensitive 235 (81.3) 18 (94.7) 187 (81.7) 33 (78.6)
  Methicillin-resistant 51 (17.7) 1 (5.3) 42 (18.39 9 (21.4)
Coagulase negative Staphylococcus 122 (29.7) 8 (29.6) 90 (28.2) 23 (35.4)
  Methicillin-sensitive 67 (54.9) 3 (37.5) 51 (56.7) 12 (52.2)
  Methicillin-resistant 55 (40.6) 5 (62.5) 39 (43.3) 11 (47.8)
Polymicrobial infection 107 (26) 4 (14.8) 87 (27.3) 16 (24.6)
Delay between prosthesis implantation and infection diagnosis, n (%)
  < 3 months 196 (47.7) 13 (48.1) 147 (46.1) 36 (55.4)
 3–12 months 85 (20.7) 5 (18.5 68 (21.3) 12 (18.5)
  > 12 months 130 (31.6) 9 (33.3) 104 (32.6) 17 (26.2)
Rifampicin treatment
 Dosage, mg/kg/day (mean,[IQR]) 15.7 [12.8–18] 8.7 [8–9.8] 14.8 [12.9–16.7] 22.9 [20.7–24]
 Full treatment course, n (%) 321 (78.1) 18 (66,6) 55 (84) 248 (77,7)
Combination treatment used
 Fluoroquinolones 278 (67.6) 20 (74.1) 214 (67.4) 44 (67.7)
 Clindamycin 64 (15.6) 5 (18.5) 51 (16) 8 (12.3)
 Glycopeptides 36 (8.7) 0 (0) 28 (8.8) 8 (12.3)
 Cotrimoxazole 17 (4.1) 1 (3.7) 13 (4.1) 3 (4.6)
 Penicillin 6 (1.5) 0 (0) 6 (1.9) 0 (0)
 Cephalosporins 2 (0.49) 1 (3.7) 1 (0.3) 0 (0)
 Doxycyclin 2 (0.49) 0 (0) 2 (0.6) 0 (0)
 Daptomycin 2 (0.49) 0 (0) 1 (0.3) 1 (1.5)
 Oxazolidinone 2 (0.49) 0 (0) 1 (0.3) 1 (1.5)
 Fosfomycin 1 (0.24) 0 (0) 1 (0.3) 0 (0)
 Dalbavancin 1 (0.24) 0 (0) 1 (0.3) 0 (0)
  1. * One or more criteria among the following: active neoplasia dating less than 1 year; immunosuppressive treatment including systemic steroids, chemotherapy or immunomodulatory drugs
  2. ** Shoulder, humerus, elbow, forearm, hand
\